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ABSTRACT A significant number of infants acquire HIV-1 through their infected moth-
er’s breast milk, primarily due to limited access to antiretrovirals. Passive immunization
with neutralizing antibodies (nAbs) may prevent this transmission. Previous studies, how-
ever, have generated conflicting results about the ability of nAbs to halt mother-to-child
transmission (MTCT) and their impact on infant outcomes. This study compared plasma
neutralizing activity in exposed infants and the infected mothers (n  63) against heter-
ologous HIV-1 variants and the quasispecies present in the mother. HIV-exposed unin-
fected infants (HEU) (n  42), compared to those that eventually acquired infection (n 
21), did not possess higher nAb responses against heterologous envelopes (P  0.46) or
their mothers’ variants (P  0.45). Transmitting compared to nontransmitting mothers,
however, had significantly higher plasma neutralizing activity against heterologous enve-
lopes (P  0.03), although these two groups did not have significant differences in their
ability to neutralize autologous strains (P  0.39). Furthermore, infants born to mothers
with greater neutralizing breadth and potency were significantly more likely to have a
serious adverse event (P  0.03). These results imply that preexisting anti-HIV-1 neutral-
izing activity does not prevent breast milk transmission. Additionally, high maternal neu-
tralizing breadth and potency may adversely influence both the frequency of breast milk
transmission and subsequent infant morbidity.
IMPORTANCE Passive immunization trials are under way to understand if preexist-
ing antibodies can decrease mother-to-child HIV-1 transmission and improve infant
outcomes. We examined the influence of preexisting maternal and infant neutraliz-
ing activity on transmission and infant morbidity in a breastfeeding mother-infant
cohort. Neutralization was examined against both the exposure strains circulating in
the infected mothers and a standardized reference panel previously used to esti-
mate breadth. HIV-exposed uninfected infants did not possess a broader and more
potent response against both the exposure and heterologous strains compared to
infants that acquired infection. Transmitting, compared to nontransmitting, mothers
had significantly higher neutralization breadth and potency but similar responses
against autologous variants. Infants born to mothers with higher neutralization re-
sponses were more likely to have a serious adverse event. Our results suggest that
preexisting antibodies do not protect against breast milk HIV-1 acquisition and may
have negative consequences for the baby.
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In the absence of intervention, approximately 60% of infants born to HIV-infectedmothers will escape infection despite constant exposure to the virus in utero, during
labor, and throughout breastfeeding (1, 2). Multiple factors, such as maternal virus level,
maternal immunologic status, the presence of other infections, and human leukocyte
antigen concordance, are known to influence transmission frequency (1). Antibodies
acquired by the baby from the mother during gestation and breastfeeding may also
prevent transmission, although previous studies have not provided a definitive answer
(3). Studies have also suggested that the acquired maternal antibodies can impact
infant morbidity (4–7). The goal of this work is to investigate the influence of humoral
immunity on breastfeeding HIV-1 transmission and infant outcomes. A better under-
standing of the immune mechanisms that impact mother-to-child transmission (MTCT)
and infant mortality is crucial for developing prevention strategies to eliminate new
infections and improve infant health.
During the course of HIV-1 infection, host antibodies emerge against envelope (Env)
glycoproteins, which are composed of surface gp120 and transmembrane gp41 subunit
trimers (8). These Env spikes mediate viral entry into host cells and are the sole targets
of neutralizing antibodies (nAbs) (9). Upon binding, antibodies can prevent cell-free
virus from entering host target cells or obstruct cell-to-cell virus transfer (10, 11). Early
in infection, the host develops antibodies that block autologous virus (9), but viruses
respond by acquiring extensive Env sequence and glycosylation variation, which
confers immune evasion (12, 13). Over time, some infected individuals may develop
nAbs that can block heterologous viral variants by binding conserved Env epitopes,
such as the CD4-binding site (CD4bs), V1/V2 or V3 loop glycans, the gp120-gp41
interface, or the gp41 membrane-proximal external region (MPER) (14, 15). The ability
of these types of antibodies, termed “broadly neutralizing antibodies” (bnAbs), to
recognize diverse viral strains is termed “breadth,” while “potency” describes the
amount of nAb needed to inhibit a fixed virus inoculum (16). Broad and potent
monoclonal antibodies (MAbs) have been generated from cells obtained from individ-
uals with heterologous neutralization responses. Some of the isolated bnAbs are being
examined in passive immunization studies to prevent MTCT (17, 18).
HIV-1 vaccine efforts are focused on immunogen design capable of eliciting these
bnAbs prior to exposure (19). Although current immunogens are unable to elicit bnAbs,
it has been demonstrated that passive immunization of diverse bnAbs successfully
prevents virus acquisition in animal models, which justifies the efforts for vaccine
development (20, 21). Animal studies, however, do not account for diverse factors
present during human transmission (22). For instance, animal challenge studies are
primarily conducted with a neutralization-sensitive cell-free virus and generally with
nonphysiologic high levels of passively administered antibodies (23). In many ways,
MTCT provides an ideal model to assess if antibodies can prevent transmission among
humans because the fetus begins acquiring maternal immunoglobulins G (IgGs) as
early as 13 weeks of gestation (24). The rate of acquisition increases throughout
pregnancy, with the largest amount of transfer occurring in the third trimester (25).
Therefore, at birth, infants are primed with amounts of IgG equal to if not greater than
those of their mother (24). In the setting of HIV-1, virus-specific antibodies are efficiently
transferred to infants in utero (26) and through breastfeeding (27). The presence of high
levels of maternal nAbs in the infant peri- and postpartum represents a favorable
scenario in which neutralization of incoming maternal variants may prevent infection.
The MTCT model had been studied previously to gain a better understanding of
humoral immunity and prevention of mother-to-child transmission (PMTCT), but these
earlier investigations often yielded conflicting conclusions. Some previous results have
suggested that antibodies reduce transmission because nontransmitting mothers
(NTMs) were shown to have higher neutralizing or binding titers compared to trans-
mitting mothers (TMs) (28–30). In addition, exposed infants that eventually become
infected acquire a limited number of HIV-1 variants, even though the infected mother
harbors a diverse quasispecies (31). These infecting strains have been found to be
neutralization resistant to maternal antibodies, further suggesting that the maternal
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humoral response impacts transmission (32, 33). In contrast, some investigations have
shown an association between transmission and higher titer of neutralizing or binding
antibodies, implying maternal responses potentially enhance MTCT (34–38). These
previous studies may have yielded contrasting results because they often examined
different modes of MTCT. Indeed, recent data suggest that in utero, peripartum, and
breastfeeding transmission select for viruses with distinct characteristics with poten-
tially unique neutralization profiles (39). Importantly, only a limited number of studies
have examined infant responses (7, 40), and there has been no examination of the
preexisting nAbs present in the exposed infant against the exposure viruses—those
circulating in the infected mothers. Examination of preexisting infant nAbs, immedi-
ately prior to the time of estimated transmission, against the maternal variants is most
analogous to examining the efficacy of envisioned vaccine and passive immunization
strategies.
Infants with higher nAb levels or with antibodies that mediate cellular cytotoxicity
have also been shown to have lower mortality and morbidity (4–7). Previous studies,
however, have not adequately examined how maternal anti-HIV-1 responses influence
infant outcomes. Indeed, studies have suggested that HIV-1-exposed uninfected (HEU)
infants have higher mortality than babies born to uninfected mothers (41). Association
between maternal responses and infant outcome may provide insights into this im-
portant observation.
In this study, we examined nAbs present in 63 mother-infant pairs from a strict
breastfeeding cohort in Malawi. The neutralizing capacity of infant and maternal
plasma antibodies, present at the time of exposure, was evaluated against maternal
strains and diverse heterologous viruses to assess responses against the exposure
variants and neutralization breadth, respectively. We show that neutralization re-
sponses against the maternal strains do not differ among infants that acquired infection
(AI) compared to HEU infants and TMs versus NTMs, and it does not associate with
infant outcome. Maternal but not infant neutralization heterologous responses, how-
ever, were significantly associated with greater transmission risk and increased infant
morbidity. Overall, this study has direct relevance to proposed vaccine efforts and
ongoing passive immunization investigations as well as health outcomes for infants
born to HIV-infected mothers.
RESULTS
All maternal and infant plasma samples were obtained from the Breastfeeding,
Antiretroviral, and Nutrition (BAN) Study (42) control arm in which the enrollees did not
receive antiretroviral therapy after 7 days postdelivery. All samples from transmitting
mother-infant pairs were obtained at an average of 41 days (range, 27 to 54 days) prior
to the first infant sample with detectable HIV-1 plasma virus (see Table S1 in the
supplemental material). For two infants (99 and 2315) and three mothers (99, 2315, and
1844), pretransmission plasma samples were only available 1 day postdelivery. For
these cases, IgG was isolated from the infant and maternal sample to prevent interfer-
ence from antiretrovirals in the plasma with subsequent analysis. Mother-infant pair
1844 was the only pair in which the date of sample collection differed between mother
and infant (Table S1). Each of the 21 transmitting mother-infant pairs was matched to
two nontransmitting mother-infant pairs by maternal plasma virus level, maternal
absolute CD4 T-cell count, maternal age, and duration of time after birth (Table 1).
Breadth and potency score reflects differences in neutralization capacity
against global Env reference panel. Neutralization responses were first assessed
against a standardized reference panel consisting of 11 different Envs (43). These tests
were done to assess heterologous responses, and this was not deemed reflective of
activity against maternal strains. Neutralization against this reference panel was quan-
tified using a breadth and potency (BP) score, which was estimated as the log-
normalized average percentage of neutralization observed at one antibody concentra-
tion or plasma dilution across all 11 Envs (equation 1). Prior to examining neutralization
capacity differences among the different plasma samples, BP score differences were
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assessed for diverse bnAbs. These controls were carried out to document that the BP
score calculated using observed percentage of neutralization at one concentration
adequately captures differences in neutralization capacity. BP scores were estimated for
bnAbs directed at CD4bs (NIH-45-46, VRC01, 3BNC117, and B12), gp41 MPER (10E8,
4E10, and 2F5), V1V2 glycan (PG9 and PG16), V3 glycan (PGT128, PGT121, 10-1074), and
gp120 (2G12) and a for a nonneutralizing antibody (A32). bnAbs with higher BP scores
(NIH-45-46, VRC01, 3BNC117, 10E8, 4E10, PG9, PG16, PGT128, PGT121, and 10-1074)
clustered separately with 100% bootstrap support from the other antibodies (Fig. 1A).
bnAbs known to be more potent and with greater breadth (NIH-45-46, VRC01,
3BNC117, 10E8, PG9, PG16, PGT128, PGT121, and 10-1074) had significantly higher BP
scores (median, 0.80; range, 0.70 to 0.99) than the other bnAbs (B12, 4E10, 2F5, and
2G12) (median, 0.25; range, 0.12 to 0.58; P  0.001). Furthermore, BP scores for all
bnAbs were higher than those for the nonneutralizing antibody, A32, which was
essentially zero (BP score, 0.05), reflective of its minimal neutralization activity. A BP
score calculated using the percentage of neutralization at one antibody concentration
was also compared to a BP score calculated using the published 50% inhibitory
concentration (IC50) value (BP-IC50) (equation 2). The BP-IC50 strongly correlated with
the BP score estimated from using the observed percentage of neutralization at the
highest tested antibody concentration (P  0.0001, Spearman’s r  0.94) (Fig. 1B). In
addition, breadth assessed from the two different methods (the percentage of Envs
neutralized50% at the highest tested dilution and with an IC5025 g/ml) were also
highly correlated for the bnAbs (P  0.0002, Spearman’s r  0.87) (Fig. 1C). Thus,
assessment of the potency and breadth derived from using the percentage of neutral-
ization at the highest tested antibody concentration generated similar results to
estimates derived from using serial dilutions to calculate an IC50. For all subsequent
analyses against the reference Env panel, BP scores were estimated using the percent-
age of neutralization at the highest tested plasma concentration.
Infected and HEU infants have similar neutralization responses against the
heterologous Env panel. BP scores were compared among AI and HEU infant plasma
samples at a time immediately prior to documented HIV-1 acquisition in the infected
infant. Assessment against the standardized reference envelope panel was used to
assess neutralization breadth and not responses against the exposure viruses. Heat map
analysis showed that AI and HEU infants did not have unique neutralization fingerprints
because the two infant clusters that separated with 100% bootstrap support contained
relatively equivalent proportions of infected and uninfected infants (Fig. 2A). Interest-
ingly, some of the highest BP scores were observed among the preinfection plasma
samples (754, 1295, and 1844) and isolated IgG (2315) in four infants that eventually
acquired infection (Fig. 2A). The AI group had a higher BP (median, 0.70; range, 0.20 to
0.90) than HEU infants (median, 0.63; range, 0.42 to 0.77), although this difference was
TABLE 1 Demographics for transmitting and nontransmitting mother-infant pairsa
Demographic
parameter
Result forb:
TMs or AI infants NTMs or HEU infants
Mothers TMs NTMs
Age, yr 26 (18–36) 25 (17–36)
Time PP, days 43 (1–256) 42.50 (12–297)
CD4 cells/mm3 336 (210–1,092) 339 (240–1,145)
Log10 plasma VL 4.78 (3.32–5.80) 4.67 (1.59–5.99)
Infants AI infants HEU infants
1st day detected as HIV 83 (42–293)
Birth wt, kg 2.95 (2.30–4.00) 3.05 (2.15–4.10)
% female 28.6 38.1
% with grade 4 SAE or death 38.1 14.3
aTMs, transmitting mothers; NTMs, nontransmitting mothers; AI, acquired infection; HEU, HIV-exposed
uninfected; PP, postpartum; SAE, serious adverse event; VL, virus level.
bMedian values are shown with ranges given in parentheses.
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not statistically significant (P  0.46) (Fig. 2B). In addition, the AI infants (median,
81.82%; range, 0 to 100%) neutralized a higher percentage of the Envs in the heterol-
ogous panel compared to the HEU infants (median, 63.64; range, 22.73 to 100%), but
this difference was not statistically significant (P  0.38) (Fig. 2C). Among the AI group,
15 of the 21 infants neutralized more than half of the reference Env panel compared to
25 of 42 for the HEU group. In aggregate, there was no significant difference in
preinfection plasma neutralization capacity among infants that acquired infection
versus those that remained uninfected.
Infants receive the majority of passively acquired maternal antibodies in the third
trimester (24). At birth, infant antibody levels often exceed those found in the mother
(25), but maternal antibodies present in the infant plasma decrease over time even with
breastfeeding (40). Infant BP scores showed an inverse correlation with the number of
days between sample collection and birth (P 0.0001, Spearman’s r0.50) (Fig. 2D).
This suggests that HIV-exposed infants often possess HIV-1-specific maternal antibodies
capable of broad and potent neutralization early after birth, but the presence of these
antibodies wanes over time.
The breadth and potency of maternal plasma antibodies significantly associate
with vertical transmission and predetermined infant clinical outcomes. Infant
plasma samples collected close to birth, when maternal antibody levels are high,
FIG 1 Breadth and potency are similar as assessed by the percentage of neutralization at the highest tested antibody concentration or IC50. (A) Each square
in the heat map represents the average percentage of neutralization for each virus-MAb combination tested: 50%, yellow; 50 to 70%, light orange; 70 to 90%,
dark orange;90%, red. All MAbs were tested at a concentration of 50 g/ml. Virus subtypes are indicated by color: A, khaki; B, gray; C, turquoise; G, lime green;
AC, pink; CRF01_AE, dark green; and CRF07_BC, purple. The branches show the hierarchical clustering with bootstrap probability for 100 iterations. (B)
Correlation between BP score estimated from the percentage of neutralization value at 50 g/ml (y axis) and BP-IC50 (x axis). All IC50s are obtained from the
Los Alamos database. (C) Correlation between breadth assessed using either the percentage of neutralization at 50 g/ml (y axis) or the IC50 (x axis).
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showed the highest BP scores (Fig. 2D). Thus, BP was compared among TMs and NTMs
to assess if maternal neutralizing capacity influences breast milk transmission. Maternal
plasma samples were collected at the same time point before infection as infant plasma
samples (with the exception of 1844) (Table S1). Heat map analysis showed that
maternal samples clustered into two separate groups with 100% bootstrap support
(Fig. 3A). These two clusters contained a significantly different proportion of TMs versus
NTMs (P  0.03; with Benjamini-Hochberg [BH] correction for multiple comparisons,
P  0.06) suggesting that transmitting compared to nontransmitting mothers con-
tained a unique neutralization fingerprint. TMs (median, 0.77; range, 0.19 to 0.96) also
had a significantly higher BP score than NTMs (0.64, range 0.40 to 0.83) (P  0.03; BH,
P  0.09) (Fig. 3B). TMs (median percentage of viruses neutralized of 50%, 90.91%;
FIG 2 Infant neutralization response against a heterologous global Env panel. (A) Each square in the heat map represents the average percentage of
neutralization for each virus-plasma combination tested:50%, yellow; 50 to 70%, light orange; 70 to 90%, dark orange;90%, red. Virus subtypes are indicated
by color: A, khaki; B, gray; C, turquoise; G, lime green; AC, pink; CRF01_AE, dark green; and CRF07_BC, purple. On the left, blue denotes AI infants and green
denotes HEU infants. The branches show the hierarchical clustering with bootstrap probability for 100 iterations. (B and C) Comparison of (B) breadth and
potency score (BP) and (C) breadth alone between AI and HEU infants. Colors signify matched pairs. Each dot represents an average value from a minimum
of 2 independent neutralization experiments for each infant. (D) Correlation between infant BP score and number of days after birth that samples were
collected. The red and black dots indicate AI and HEU infants, respectively.
Ghulam-Smith et al. ®
September/October 2017 Volume 8 Issue 5 e01373-17 mbio.asm.org 6
range, 0 to 100%) also had significantly higher breadth compared to NTMs (median
percentage of viruses neutralized of 50%, 63.64%; range, 18.18 to 90.91%) (P  0.01;
BH, P 0.06) (Fig. 3C). The significantly higher BP observed in TMs was primarily driven
by neutralization against specific isolates. TMs had a significantly higher response than
NTMs against the subtype B, TRO11, subtype C, CE1176, and the recombinant
CRF07_BC, BJOX2000 Envs (see Fig. S1 in the supplemental material).
Previous studies found that passively acquired maternal antibodies may protect
infants from adverse clinical outcomes (4, 5). A more recent study found an inverse
association between passively acquired antibodies capable of antibody-dependent
cellular cytotoxicity (ADCC) and infant mortality (6). Therefore, association between
preinfection BP score and infant outcome was examined in our cohort. In this cohort,
14 infants had a grade 4 serious adverse event (SAE) or death during BAN Study
follow-up. An SAE of grade 4 or death occurred in 8 and 6 AI and HEU infants,
respectively (see Table S2 in the supplemental material). To examine the effect of BP
scores on infant outcome, we compared infants and mothers with BP scores greater
than or equal to the median cohort BP versus infants and mothers with BP scores less
FIG 3 Maternal neutralization response against a heterologous global Env panel. (A) Each square in the grid represents the average percentage of neutralization
for each virus-plasma combination tested: 50%, yellow; 50 to 70%, light orange; 70 to 90%, dark orange; 90%, red. Virus subtypes are indicated by color:
A, khaki; B, gray; C, turquoise; G, lime green; AC, pink; CRF01_AE, dark green; and CRF07_BC, purple. On the left, blue denotes transmitting mothers (TMs) and
green denotes nontransmitting mothers (NTMs). The branches show the hierarchical clustering with bootstrap probability for 100 iterations. (B and C)
Comparison of (B) breadth and potency score (BP) and (C) breadth alone between TMs and NTMs. Colors signify matched pairs. Each dot represents an average
value from a minimum of 2 independent neutralization experiments. (D) Kaplan-Meir curve estimating time (days) to a grade 4 SAE or death for infants born
to mothers with BP greater than or equal to the cohort median (red) or less than the cohort median (black).
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than the median cohort BP. Similar to the Milligan study (6), which also looked at
neutralizing antibody activity using data from the Lynch study (40), we did not observe
a significant association with infant BP score and infant outcomes (P  0.79). However,
there was a significant 3.4-fold increase in the likelihood of having a life-threatening
illness or death in infants born to mothers with high BP compared to low BP (hazard
ratio [HR], 3.39; 95% confidence interval [CI], 1.06 to 10.90; P  0.03; BH, P  0.06)
(Fig. 3D). The risk was similar for infants who acquired infection compared to those who
did not, although the results were not statistically significant, likely due in part to the
small number of events (AI HR, 2.52, 95% CI, 0.37 to 16.80, P  0.35; HEU HR, 2.40, 95%
CI, 0.48 to 12.09, P  0.29). Overall, these data demonstrate that infants born to
mothers with a pretransmission broad and potent heterologous nAb response are more
likely to both acquire HIV-1 and have a poor clinical outcome.
The emergence of heterologous neutralizing responses has been associated with a
number of factors, including duration of infection and plasma virus level (44). Therefore,
we assessed whether infant and maternal BP scores correlated with maternal clinical
characteristics. Infant BP score did not correlate with maternal viral load (P  0.16,
Spearman’s r  0.18) (Fig. 4A) or CD4 T-cell count (P  0.60, Spearman’s r  0.07)
(Fig. 4B). Maternal BP score, however, showed an inverse correlative trend with plasma
virus level (P 0.07, Spearman’s r0.23) (Fig. 4C), but there was no association with
maternal CD4 T-cell counts (P  0.62, Spearman’s r  0.06) (Fig. 4D). This suggests
that maternal viral load and maternal advanced disease did not drive the association
between maternal neutralization BP score and breast milk transmission.
Although maternal disease variables were not associated with preinfection infant BP
scores, maternal and infant BP scores were highly correlated (P 0.004, Spearman’s r
0.36) (Fig. 4E). Furthermore, the correlation between maternal and infant BP scores was
significantly associated with interval duration between birth and sample collection (P
0.01, Spearman’s r  0.32) (Fig. 4F). Maternal and infant samples obtained soon after
birth had significantly lower BP difference compared to those obtained at later time
points. Overall, this shows that infected mothers pass broad and potent HIV-1-specific
nAbs to their infants especially close to birth and these nAbs are not protective against
breast milk transmission.
Passively acquired nAbs in breastfeeding infants do not protect against infec-
tion with maternal autologous virus. HEU infants did not possess a significantly
broader or more potent antibody response than those infants that acquired HIV-1
through breast milk. However, the heterologous viral isolates, although representative
of the global population, are not the viruses infants need to neutralize in order to
escape infection. During breast milk transmission, naive susceptible infants are only
exposed to the quasispecies circulating in the chronically infected mother (31). Invari-
ably, these maternal variants are expected to be dramatically different from the
envelopes in the reference panel. We hypothesized that HEU compared to AI infants
had a higher nAb response against their maternal variants. To examine this hypothesis,
we isolated Envs from the maternal predocumented transmission plasma.
A recent study in lactating Malawian women found interspersion of plasma and
breast milk HIV Env sequences, suggesting limited or no compartmentalization of
breast milk variants (45). Furthermore, we have demonstrated that virus stocks incor-
porating either bulk PCR generated or a library of single-genome PCR-amplified Envs
have similar neutralization susceptibility (46). Therefore, bulk PCR or a pool of enve-
lopes amplified by single-genome amplification (SGA) were incorporated into an HIV-1
backbone to generate maternal virus stocks (see Table S3 in the supplemental material).
Rather than testing neutralization against individual Envs, this nonselective methodol-
ogy allowed assessment against quasispecies circulating in the infected mothers.
Replication-competent viruses incorporating maternal Envs were successfully gener-
ated from 14 TMs and 23 NTMs. Among AI infants, 4 of 14 neutralized their mother’s
virus above 50% at the highest tested plasma dilution (1:50) compared to 9 of 23 in the
HEU group (P 0.52). As many of the maternal and infant plasma samples did not yield
50% inhibition, the area under the inhibition curve (AUC) was calculated by taking the
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average neutralization within the range of dilutions tested for each antibody-virus
combination (47). This yielded values ranging from 0 to 1, with 1 representing the most
potent plasma neutralization response and 0 representing no neutralization (Table S3).
There was a significant correlation between IC50 and corresponding AUC (P  0.0001,
Spearman’s r  0.76) among the samples in which 50% or greater inhibition was
observed at the highest tested dilution (see Fig. S2 in the supplemental material). This
strong correlation suggests that AUC can be used as a correlate for IC50 and group
comparisons using AUC can be done without excluding cases in which 50% inhibition
could not be achieved. The median AUC in the AI group was 0.16 (range, 0.00 to 0.37),
compared to 0.25 (range, 0.00 to 0.49) in the HEU group. Neutralizing activity against
autologous maternal viruses was not significantly different when AI and HEU were
examined as independent groups (P  0.30) (Fig. 5A) or when comparing matched
infant pairs (n  14; P  0.45) (Fig. 5B). In aggregate, HEU infants, compared to AI
infants did not have greater neutralization capacity against their corresponding moth-
er’s variants.
FIG 4 Infant and maternal BP score correlations. (A to F) Correlation between (A) infant BP score and maternal plasma virus
level, (B) infant BP score and maternal CD4 T-cell counts, (C) maternal BP scores and maternal plasma virus level, (D)
maternal BP scores and maternal CD4 T-cell counts, (E) infant and maternal BP scores, and (F) difference between
maternal and infant BP scores and interval duration between birth and sample collection. The red dots indicate TMs and
their AI infants. The black dots indicate NTMs and their HEU infants.
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While overall ability to neutralize their mothers’ virus did not differ among the HEU
and AI groups, there were cases where infants had high neutralization capacity against
maternal autologous virus but relatively limited neutralization responses against the
global reference Env panel. Indeed, infant AUC against its maternal virus did not show
a significant correlation with BP score (P  0.21, Spearman’s r  0.21) (Fig. 5C). This
implies that, in infants, the neutralization response to heterologous virus is distinct from
the neutralizing activity against the maternal exposure virus.
Maternal neutralization against autologous virus does not predict transmis-
sion risk. Over the course of infection, viruses evolve and the majority of circulating
viruses are neutralization resistant to contemporaneous plasma (9). A higher proportion
of TMs (5 of 14 [36%]) compared to NTMs (6 of 23 [26%]) neutralized their autologous
virus above 50% at the highest tested plasma dilution, although this frequency differ-
ence was not statistically significant (P  0.53). The TMs (median, 0.22; range, 0.02 to
0.44) had higher AUC against autologous virus than the NTMs (median, 0.15; range, 0.00
to 0.36), but this difference was also not statistically significant when examined as
independent groups (P  0.26) (Fig. 6A) or matched pairs (n  14; P  0.39) (Fig. 6B).
In contrast to the infants, maternal AUC significantly correlated with their BP scores
(P  0.01, Spearman’s r  0.42) (Fig. 6C). This concurs with a similar observation in a
different cohort that also suggested that TMs have higher nAbs against heterologous
and autologous viruses (48).
DISCUSSION
In this study, we compared heterologous and autologous HIV-1-specific plasma
antibody responses from subtype-C-infected TMs and NTMs and their respective in-
fants. As participants in the control arm of the BAN Study (42), transmission mode was
FIG 5 Neutralization response against maternal variants among infants that acquired infection and those that remained uninfected. (A and B) Area under the
inhibition curve (AUC) values among AI versus HEU infants examined as (A) independent groups (Mann-Whitney test) and (B) matched pairs (linear regression
model). Colors signify matched pairs for both analyses. (C) Correlation between infant AUC neutralization response against maternal strains and heterologous
virus (BP score). The red and black dots indicate AI and HEU infants, respectively.
FIG 6 Autologous neutralization response among transmitting and nontransmitting mothers. (A and B) Autologous neutralization represented by (A) area
under the neutralization curve (AUC) between TMs and NTMs examined as (A) independent groups (Mann-Whitney test) and (B) matched pairs (linear regression
model). Colors signify matched pairs for both analyses. (C) Correlation between maternal neutralization response against autologous virus (AUC) and
heterologous virus (BP score). The red and black dots indicate TMs and NTMs, respectively.
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restricted to the breastfeeding period. Utilizing this unique cohort, we found that
although HIV-1-specific nAbs were efficiently transferred from mother to infant; they
were not a correlate of protection from HIV-1 breast milk acquisition. Indeed, we
observed that some of the infants with the highest neutralization BP were infected
through breastfeeding. Surprisingly, HIV-1-infected TMs compared to NTMs harbored
greater pretransmission neutralization breadth and potency. Furthermore, infants born
to mothers with higher pretransmission neutralization responses were more likely to
have a serious adverse outcome. In summary, these data argue that in a natural HIV-1
transmission setting, presence of nAbs during exposure but prior to transmission does
not protect against HIV-1 acquisition. Additionally, higher levels of anti-HIV-1 neutral-
izing responses in the mother associate with both transmission and infant morbidity.
Vaccine efforts or passive immunization protocols aim to have bnAbs present prior
to HIV-1 exposure in susceptible individuals (49). Although animal models have dem-
onstrated remarkable success in preventing infection when bnAbs are present prior to
exposure (20, 21), it remains unclear if similar efficacy will be evident in natural human
HIV-1 transmission (23). Examination of transmission frequency differences among
individuals that harbor neutralization responses during exposure, similar to those
envisioned by vaccine efforts and passive immunization protocols, is one way to
partially explore this important question. Using a standardized panel of global Envs
(43), we calculated a BP score to characterize the neutralization capacity in a plasma
sample. Importantly, prior to plasma analysis, previously well-characterized bnAbs were
used to validate that determination of neutralization at one concentration, as opposed
to calculating an IC50, adequately captures differences in neutralization capacity (Fig. 1).
AI infants compared to HEU had similar neutralization responses against the global Env
panel (Fig. 2). This highlights that while some infants possessed antibodies capable of
blocking diverse primary HIV-1 strains that have limited neutralization susceptibility,
this combination of breadth and potency is not a correlate of protection. Our results
obtained from a large number of mother-infant pairs in a strict breastfeeding subtype
C transmission cohort confirm conclusions from a different study of mostly subtype
A-infected individuals using a smaller, less diverse panel of viruses (40). In contrast to
the prior investigation, in our study, samples were collected at a time point both close
to and prior to infection instead of at birth. This is important because antibodies
acquired by the infant from the mother decrease after birth even with breastfeeding
(40). Because the global envelope panel does not adequately represent the maternal
quasispecies, we also compared exposed infants’ ability to block infection from the
circulating maternal viruses. To our knowledge, this is the first study that has examined
the infant’s ability to block the exposure viruses. Thus, our investigation is the most
direct test of preinfection neutralization capacity in restricting HIV-1 acquisition be-
cause we examined infant responses against circulating maternal strains during the
narrow window of time prior to transmission.
We observed a number of infants that possessed antibodies with extensive breadth
and potency prior to infection, and yet they nevertheless acquired the virus from their
mother. There are a number of reasons these infants may have become infected even
though they had neutralization responses analogous to those that may be provided by
bnAbs. First, these infants likely became infected with maternal variants that were
resistant to the transplacental and breast milk-acquired nAbs. Therefore, in contrast to
animal models in which challenge viruses are invariably sensitive to the nAbs under
investigation (23), human transmission can occur with variants that are resistant to the
preinfection existing nAbs. Second, breast milk contains both cell-free virus and in-
fected cells (50–52). We and others have previously demonstrated that even though
nAbs potently inhibit cell-free virus, they may be less efficient in blocking cell-to-cell
transfer (11, 53). Thus, unlike most animal models in which challenges consist of
cell-free virions (23), human transmission may occur from an infected cell, and this
mode of spread may be less susceptible to antibody inhibition. Third, we assessed
neutralization capacity in infant plasma, yet nAb responses may be different at the site
of virus acquisition, namely, the oral or gastrointestinal mucosa (54). Therefore, it is
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possible that passive immunization strategies alone may not yield adequate antibody
levels at mucosal sites of invasion (55). Our studies suggest that breast milk HIV-1
transmission can occur even in the presence of potent and broad preinfection neu-
tralization capacity in susceptible individuals.
While nAbs present in the infant at the time of infection do not protect against
infection, this does not preclude the possibility that the presence of greater neutral-
ization capacity in the infected mother limits transmission (33, 56). Contrary to this
proposed protective role, however, we observed that TMs compared to NTMs had
significantly higher neutralization BP (Fig. 3). Interestingly, other studies have also
observed that TMs or transmitting mother-infant pairs have greater neutralization
capacity than NTMs or nontransmitting mother-infant pairs (34–36, 38). In comparison
to our study, these other investigations differ in many important ways, such as the
number of individuals, use of either pre- or postinfection infant plasma, examination of
in utero to postpartum MTCT, presence of different HIV-1 subtypes, and lack of relatively
equivalent plasma virus levels and absolute CD4 T cells among the transmitting versus
the nontransmitting group. Even with these differences, surprisingly, these studies have
yielded a consistent theme that greater neutralization capacity is associated with
higher MTCT frequency. The biological reasons for this recurrent observation remain
unclear. It is possible that a higher maternal HIV-1 antibody response may enhance
transmission by forming HIV-1-IgG immune complexes that bind to the neonatal Fc
receptor (FcRn) in the infant gastrointestinal tract or Fc-gamma receptors (FcRs) on
immune cells such as macrophages or dendritic cells. This attachment may facilitate
subsequent viral migrations across mucosal surfaces (57–60). This antibody-dependent
enhancement (ADE) hypothesis remains highly controversial primarily because there
are in vitro studies that both support (61–63) and refute it (64). Interestingly, there is in
vivo support for this idea because animals given antibody infusion compared to sham
treatment were more likely to have virus present at distal tissues from the site of
inoculation, suggesting that antibodies may enhance transport across mucosal barriers
(65). Analogously, in a randomized trial HIV Ig infusion along with nevirapine (NVP) at
the onset of labor was associated with a higher infant infection rate at birth compared
to the group that received NVP alone (66). Although ADE was deemed unlikely to
account for this curious observation, over subsequent follow-up, infection rates were
the same in the two groups, potentially as HIV Ig concentrations decreased (66). Taken
together, the observed reasons for the positive association between maternal neutral-
ization capacity and transmission frequency during MTCT remain a recurring unex-
plained finding with potentially profound implications for passive immunization strat-
egies.
In addition to a high BP score predicting infection, we also demonstrate an associ-
ation between high BP and greater likelihood of the infant dying or suffering an SAE
(Fig. 3D). This finding was not merely driven by the association of higher BPs among
TMs because events were present both in the infected and uninfected infants (Ta-
ble S2). HEU infants are known to have worse outcomes than infants born to HIV-
uninfected mothers, although the reason remains unclear (67). Some postulate that
exposure to circulating viral antigens is immunosuppressive in HEU infants (68, 69). An
alternative hypothesis could be that high levels of broad and potent nAbs in mothers
may reduce the transfer of IgGs against other potentially harmful pathogens, such as
tetanus (70) and measles (71) or may alter the infant humoral response (72). On the
other hand, infected infants that acquired HIV-1 from mothers with broad and potent
nAb responses may have had poorer outcomes because they were infected with a
greater variety of or more pathogenic variants. Neutralization breadth and potency
have been associated with length of infection and HIV-1 genotypic diversity (44, 73).
Mothers with high BP and a greater variety of circulating viruses may be more likely to
transmit diverse or more pathogenic strains to their breastfeeding infants. Indeed,
infection with multiple variants as opposed to a single variant has been associated with
faster disease progression (74, 75). A high maternal neutralizing response prior to
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transmission has not been previously associated with unfavorable infant outcomes, and
further studies in different cohorts are warranted.
Our results do confirm that infants acquire HIV-1-specific nAbs from their infected
mothers. Maternal BP scores correlated with infant BP scores, and this correlation was
strongest at the earliest time points after birth (Fig. 4). In addition, there was a
significant correlation between sample time postbirth and infant BP (Fig. 2C). This
implies that infants acquire maternal anti-HIV-1 specific nAbs after birth, and over time
infants have de novo-generated non-HIV-1-directed antibodies, which dilutes the HIV-
directed humoral component. The fact that the risk of breast milk transmission is
greatest in the first 6 weeks’ postpartum (76), at a time when maternal antibody titers
are at their highest, indirectly further suggests a lack of protection in the face of broad
and potent HIV-1-specific nAbs.
Passively acquired preinfection nAbs against a heterologous Env panel did not
distinguish infected versus HEU infants; however, neutralization of maternal variants,
which are responsible for producing infection, is more meaningful in determining
protection against exposure strains. AI compared to HEU infants had similar ability to
neutralize their maternal exposure quasispecies (Fig. 5), but the majority of infants in
both groups did not have a strong neutralizing response to their corresponding
maternal virus as most did not reach 50% neutralization (Table S3). Remarkably, some
infants with strong responses to heterologous viruses in the reference Env panel were
unable to neutralize autologous maternal virus. This suggests that transmission occurs
with a virus that may be resistant to a broadly neutralizing response, similar to what
may exist with bnAb passive infusions (77). Most likely, however, maternal viruses are
resistant to autologous antibodies acquired by the infant rather than harboring broad
resistance against diverse bnAbs. Some infants that acquired HIV-1 demonstrated an
ability to block the exposure quasispecies circulating in the infected mother. These
infants may harbor antibodies that are capable of efficiently blocking maternal variants
during cell-free but not cell-to-cell transfer. Future studies should compare the ability
to block cell-to-cell spread among the preinfection plasma samples from infected and
uninfected infants that had relatively high neutralization capacity against cell-free
viruses with maternal Envs.
The TMs compared to NTMs had higher neutralization responses against autologous
virus, but the difference was not statistically significant (Fig. 6). The same trend was also
observed in a recent study comparing TMs and NTMs infected with mostly subtype A
HIV-1 (48). In general, most mothers harbored quasispecies that were not susceptible
to autologous antibodies (Table S3), confirming that most contemporaneous viruses
escape neutralization responses (12, 13). Together, these data suggest that transmitting
compared to nontransmitting mothers do not harbor more resistant variants that can
escape neutralization and lead to transmission because NTMs and TMs harbor variants
with similar susceptibility to autologous antibodies. Although the conservative BH
adjustment yielded P values that suggest a statistical trend rather than significance, in
every instance, greater maternal neutralization response was positively associated with
an adverse outcome, which provides further support for our overall conclusions.
It is possible that antibody responses present in the breast milk are different from
the ones in the blood. It is well known that breast milk contains a larger amount of
IgA compared to blood, which primarily has IgG isotypes. A recent study found no
significant difference in the ability of antibodies present in the breast milk to neutralize
three different HIV variants among TMs and NTMs from the BAN cohort, although,
breast milk HIV-specific IgA binding to a consensus HIV-1 Env gp140 was associated
with a decreased risk of transmission (56). It has been hypothesized that secretory IgA
(sIgA), which is enriched in breast milk, is blocking infection at the infant gastrointes-
tinal mucosa (78, 79). HIV sIgA, however, is rarely detected in the saliva of HEU infants
(80). Interestingly, Kuhn and others (81) detected sIgA significantly more often in the
breast milk of TMs compared to NTMs, and IgA from infected individuals has been
presumed to mediate enhancement of HIV infection in vitro (82). It is difficult to directly
compare our finding to the previous sIgA studies, but there is no definitive evidence
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that preexisting maternal antibody response protects against breast milk HIV-1 trans-
mission.
Using a natural infection model, our data suggest that preexisting antibodies with
cross-reactive potential do not protect against subtype C breast milk transmission. An
important consideration is that this study only assessed neutralization. Other antibody
functionalities, such as ADCC, may play a role in providing protection, as was observed
in the secondary analysis of RV144 vaccine trial in Thailand (83). Indeed, a recent MTCT
study suggested a role of ADCC in protection from breast milk transmission in mothers
with high viral load (84). Other investigations, however, found no association between
ADDC present in the infant plasma or maternal breast milk and infant transmission risk
(6, 56). Future studies that examine other antibody functionalities, especially against
the exposure variants circulating in the infected mothers, are needed. These types of
studies will provide insights for future vaccine efforts, passive immunization strategies,
and factors associated with infant morbidity.
MATERIALS AND METHODS
Ethics statement. The BAN Study was approved by the Malawi National Health Science Research
Committee, the institutional review boards at the University of the North Carolina, the U.S. Centers for
Disease Control and Prevention, and Boston University. All women provided written informed consent for
themselves as well as on behalf of their infants. Buffy coats from anonymized uninfected donor
volunteers were obtained from the Kraft Family Blood Donor Center at the Dana Farber Cancer Center
after written informed consent.
Study cohort. Mother and infant plasma samples were acquired from the control group of the BAN
Study. The BAN Study compared a maternal combination antiretroviral therapy (cART) regimen, infant
nevirapine, or no therapy after the peripartum period in HIV-1 breast milk transmission frequency
(ClinicalTrials.gov no. NCT00164736). All mother-infant pairs examined in this study were treated
peripartum with single-dose oral nevirapine followed by zidovudine-lamivudine (ZDV-3TC) for 7 days
postpartum. This brief peripartum treatment in the control arm was deemed ineffective to prevent
subsequent breast milk HIV-1 transmission, and it was deemed likely to have an insignificant impact on
the maternal Env quasispecies or antibody repertoire. An infant negative-DNA PCR at birth and 14 days
postpartum was required for enrollment to rule out intrauterine and intrapartum transmission. Mothers
were instructed to exclusively breastfeed for 24 weeks, and mother-infant pairs were followed and tested
with sample collection at regular intervals for 48 weeks (42). An infant was deemed as having acquired
infection through breast milk when HIV-1 RNA was detected in a follow-up plasma sample and the
previously collected sample was negative. All infant samples examined in this study were obtained prior
to the documented HIV-1 acquisition. Each infant that eventually acquired infection and the correspond-
ing transmitting mother were matched to two mother-infant pairs with no documented transmission
based on maternal plasma virus level, maternal CD4 T-cell counts, and days postpartum to sample
collection.
Antibodies. The following MAbs were obtained from the National Institutes of Health (NIH) AIDS
Reagent Program: VRC01, NIH-45-46, 10E8, 3BNC117, PG9, PG16, PGT121, PGT128, 10-1074, 4E10, 2F5,
2G12, B12, and A32. For maternal and infant plasma samples collected within the first 7 days after birth
(maternal, 99, 1844, and 2315; infant, 99 and 2315), IgG was isolated using the Melon gel IgG spin
purification kit (Thermo Scientific, Pierce Biotechnology) according to the manufacturer’s instructions.
The concentration of collected IgG was measured on the NanoDrop 2000 spectrophotometer (Thermo
Scientific) and stored at 4°C for downstream use. An equivalent amount of isolated IgG to that present
in a 1:50 plasma dilution was used in the subsequent neutralization assays.
Cell cultures. Human epithelial kidney HEK293T cells and TZM-bl cells were acquired from the NIH
AIDS Reagent Program. Cells were maintained in Dulbecco’s modified Eagle medium (DMEM) with 10%
fetal bovine serum (FBS) (Thermo Fisher Scientific), 2 mM L-glutamine, 100 U of penicillin per ml, and
100 g of streptomycin per ml. Peripheral blood mononuclear cells (PBMCs) were purified using the
Ficoll-Hypaque method from at least 3 separate HIV-seronegative donors and propagated in RPMI 1640
containing 10% FBS, 100 g/ml penicillin-streptomycin, 5 g/ml of phytohemagglutinin (Sigma), and
interleukin-2 for 4 days prior to infection.
Envelope isolation and amplification. Expression plasmids for the 12 rev-env cassettes selected as
global reference strains were acquired from the NIH AIDS Reagent Program. These 12 Envs were
previously deemed to best represent the spectrum of neutralizing activity of a larger Env panel (43). Env
amplicons were generated using PCR with primers IR delta ecto (5=-AAGCCTCCTACTATCATTAT) and
envb3 out (5=-TTGCTACTTGTGATTGCTCCATGT) under previously described conditions (85). The QIAamp
viral RNA isolation kit (Qiagen) was used to isolate RNA from maternal pretransmission plasma that was
also used for the neutralization assessments. Envs were amplified using single-genome amplification
(SGA) or bulk PCR under previously described conditions (86). All SGA-amplified amplicons or minimum
of 3 independent bulk PCRs were pooled to generate a library of maternal Envs (Table S3).
Replication-competent virus stocks. Maternal Env pools and reference Envs were inserted into a
subtype C T/F plasmid, pZM247Fv2 (87), and NL4-3 (AF324493) plasmid, respectively, using yeast gap
repair homologous recombination with minor modifications from previously described methods (88, 89).
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Virus stocks were generated from HEK293T transfections as described previously (88). Briefly, HEK293T
cells were cotransfected with a cytomegalovirus–NL4-3–long terminal repeat¡Gag4 (CMV-NL4-3-
LTR¡Gag4) plasmid and a recombinant NL4-3 plasmid incorporating a reference Env or CMV-Q-23-
LTR¡Gag4 plasmid and plasmid pools incorporating maternal Envs. The supernatant was harvested 48 h
posttransfection, filtered through a 0.45-m-pore filter, and stored at 80°C. The 293T virus was
passaged on PBMCs for a maximum of 7 days. At harvest, supernatants were centrifuged, filtered through
a 0.45-m-pore filter to remove cellular debris, and stored at 80°C. Titers of virus stocks were
determined on TZM-bl cells in the presence of 10 g/ml DEAE-dextran. A replication-competent virus
could not be generated for reference panel subtype C Env CE0217, and thus the heterologous Env panel
used in this study consisted of 11 variants.
Neutralization assay. All maternal and infant plasma samples were heat inactivated for 1 h at 56°C.
All neutralization assays were performed in duplicate or triplicate a minimum of 2 independent times
using TZM-bl cells as described previously (33). Briefly, neutralization of viruses incorporating maternal
Envs was tested against 1:50 maternal or infant plasma and 2-fold serial dilutions. Neutralization of
viruses incorporating a reference Env from the global panel was tested against either a 1:50 plasma
dilution, an equivalent amount of isolated IgG to that present in a 1:50 plasma dilution, or 50 g/ml MAb.
A NL4-3 Env-deleted vesicular stomatitis virus G protein Env pseudotype was also used as a negative
control in panel neutralizations. Virus was incubated with antibody, heat-inactivated plasma, or growth
medium alone in a total volume of 50 l for 1 h at 37°C, and approximately 1E5 TZM-bl cells with
10 g/ml DEAE-dextran was added to each well after this incubation. After 48 h, infection levels were
determined using Galacto-Light Plus (Applied Biosystems, Foster City, CA). Differences between relative
light units (RLU) in the presence of antibody or plasma and growth medium alone were calculated as the
percentage of neutralization. Background RLU in the TZM-bl cells alone were subtracted from all wells.
Statistical analysis. Neutralization responses against the global reference Env panel for each plasma
sample and MAb were summarized by two different but related estimates. The first estimate, termed
“breadth-potency” (BP), incorporated both the amount of neutralization against an Env at either a 1:50
plasma dilution or 50 g/ml MAb concentration and responses against the entire 11 Env panel. BP was
estimated by averaging the percentage of neutralization across all 11 Envs, and in this calculation, an
Env-plasma/MAb combination that yielded a negative percentage of neutralization was assigned a value
of 0. This mean was log2 transformed so the score ranged from 0 to 1, with 0 representing no
neutralization and 1 being 100% neutralization against all Envs, as shown in equation 1:
BPlog2(% neutralization ⁄ 100 1) ⁄ 11 (1)
The second estimate, termed “breadth,” was defined as the percentage of Env variants neutralized at
50% at the highest tested plasma/MAb concentration. As opposed to BP, breadth did not incorporate
the observed degree of neutralization against an Env.
For autologous variants, an IC50 was calculated as the dilution that gave 50% inhibition. Cases were
assigned an IC50 of 25 (half of the highest tested plasma dilution) when 50% inhibition was not observed.
AUC was also estimated because IC50 could not be estimated for a large number of samples (47).
Differences in frequencies among two groups were examined using a two-sample test of proportions.
Differences among groups were analyzed using the Wilcoxon matched-pair test, and for these compar-
isons, average values were used for the 2 controls matched to each case. Linear regression models were
also fit with generalized estimating equations (GEEs) because averaging estimates from the 2 matched
controls for each case is not always deemed ideal. All measures were arcsine transformed for better fit
in the GEE models. We considered nutrition supplementation, infant birth weight, maternal age, infant
death, and serious adverse events (SAEs) in the infant as potential confounders of the relationship
between AI and HEU infants and between TMs and NTMs and each of the scores of interest (BP, breadth,
and AUC). Results were similar between the Wilcoxon matched-pair test and linear regression models;
therefore, only P values from the latter are reported. Spearman’s rank tests were used to examine
correlation among all continuous variables.
BP and breadth scores were also calculated for MAbs using published IC50s against the global
reference Env panel variants. The IC50s of an antibody against a specific reference Env was obtained from
the Los Alamos database (http://hiv.lanl.gov/catnap) (90). This MAb BP-IC50 score was generated using
equation 2:
BP-IC50log2(2 IC50 ⁄ highest tested concentration) ⁄ 11 (2)
In cases, where an IC50 could not be estimated because 50% neutralization could not be achieved,
IC50 was set as the highest tested antibody concentration. The BP-IC50 approaches 1 for the potent
antibodies that have low IC50 against the majority of virus variants. The BP-IC50 is 0 for MAbs that
demonstrate no neutralization capacity. Breadth was defined as the percentage of reference Envs
neutralized with an IC50 of 25 g/ml.
Clinical adverse events for these infants were graded by the BAN Study investigators prior to our
sample evaluations and according to toxicity tables from the Division of AIDS at the National Institute of
Allergy and Infectious Diseases (NIAID) (42). We used Cox proportional hazard models to study the risk
of grade 4 SAE or death as a function of BP score and adjusted for the matching in the data by using a
robust estimate of the standard errors. For this analysis, BP scores were dichotomized as high (BP score
 cohort median) versus low (BP score  cohort median). Nutrition, maternal age, and infant birth
weight were considered potential confounders in this model. We also considered an analysis stratified by
HIV status of the infant.
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The BH correction was used to control for possible inflation of the type I error rate due to multiple
testing. The adjusted P value with BH correction is presented for instances of multiple comparisons
where the unadjusted P value is 0.05.
Heat map. Heat maps were generated using the Los Alamos HIV sequence database heat map tool
(https://www.hiv.lanl.gov/). All heat maps used hierarchical clustering with the Euclidean distance
method. Bootstraps were generated using standard procedure in the Los Alamos tool.
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